ACC.25 – Diego Sadler reviews the results from the API-CAT study, which examined the efficacy and safety of low-dose apixaban versus full dose in patients with cancer-associated VTE. According to Sadler, it is good news for this patient population that the lower dose does not appear to be less effective and has a good safety signal.
Low-dose apixaban noninferior to full dose in cancer-associated VTE

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Educational information
This video was recorded during the ACC.25 Scientific Session Chicago, IL, USA.
Faculty
Diego Sadler, MD is section head Cardio-Oncology at the department of Cardiovascular Medicine AT Cleveland Clinic Florida in Weston, FL, USA. He is chair-elect of the ACC Cardio-Oncology Council.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 18 April 2025
The findings of this study were simultaneously published in N Engl J Med.
The information and data provided in this program were updated and correct at the time of its development, but may be subject to change.
Overview
ACC.25 – Diego Sadler reviews the results from the API-CAT study, which examined the efficacy and safety of low-dose apixaban versus full dose in patients with cancer-associated VTE. According to Sadler, it is good news for this patient population that the lower dose does not appear to be less effective and has a good safety signal.
Educational information
This video was recorded during the ACC.25 Scientific Session Chicago, IL, USA.
Faculty
Diego Sadler, MD is section head Cardio-Oncology at the department of Cardiovascular Medicine AT Cleveland Clinic Florida in Weston, FL, USA. He is chair-elect of the ACC Cardio-Oncology Council.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 18 April 2025
The findings of this study were simultaneously published in N Engl J Med.
The information and data provided in this program were updated and correct at the time of its development, but may be subject to change.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
Updates From the 7th World Symposium Task Force
Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies
Partnering with Patients: Building Effective Communication and Support in HF Care
Clinical Conundrums in ARIA: Nuances of Microhemorrhages when Evaluating an MRI for ARIA
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?